Use of BMPR1b inhibitor in induced development, and induction culture medium

By using the BMPR1B inhibitor pyrazolecarboxylpiperazine ketone compounds in the induction medium to bind to the BMPR1B receptor, the problem of controlling the differentiation direction of pluripotent stem cells was solved, and the efficient differentiation of pluripotent stem cells to neural lineage cells was achieved. Neurological disease treatment provides new avenues.

WO2024239187A1PCT designated stage expired Publication Date: 2024-11-28IREGENE THERAPEUTICS LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/095448
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively control the BMPR1B receptor and then regulate the differentiation direction of pluripotent stem cells, especially in the induction of neural lineage cells.

Method used

An induction medium containing a BMPR1B inhibitor is provided, which forms a stable complex with the BMPR1B receptor through a specific pyrazolecarboxylpiperazine ketone compound, regulates downstream gene expression to promote the differentiation of pluripotent stem cells into neural lineage cells.

Benefits of technology

The efficient and directed differentiation of pluripotent stem cells into neural lineage cells is achieved, providing a potential pathway for the treatment of neurodegenerative diseases and nerve injury, and has low physiological toxicity and high binding energy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023095448_28112024_PF_FP_ABST
    Figure CN2023095448_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of biological medicines, and in particular to a use of a BMP1B inhibitor in induction development, an induction culture medium, and an induction method. The induction culture medium comprises a BMPR1B inhibitor having a structure represented by formula I, or a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope marker, isomer or prodrug of the structure represented by formula I.
Need to check novelty before this filing date? Find Prior Art

Description

Application of BMPR1B inhibitors in induced development, induction culture medium Technical Field

[0001] The present application relates to the field of biomedicine technology, and in particular to an application of a BMPR1B inhibitor in inducing development and an induction culture medium. Background Art

[0002] Transforming growth factor-β (TGF-β) belongs to the TGF-β superfamily and plays a crucial role in regulating cell growth and differentiation. There are two main types of TGF-β cell membrane receptors: TGF-β type I receptor and TGF-β type II receptor. In vertebrates, there are seven known type I receptors (activin-receptor like kinases): ALK1 (ACVRL1), ALK2 (ACVR1), ALK3 (BMPR1A), ALK4 (ACVR1B), ALK5 (TGFBR1), ALK6 (BMPR1B), and ALK7 (ACVR1C); and five type II receptors: TGFβRⅡ, ACTRⅡ, ACTRⅡB, BMPRⅡ, and AMHRⅡ.

[0003] Among them, ALK6, a type I receptor, also known as BMPR1B (bone morphogenetic protein receptor, type IB), is an important transmembrane receptor protein that plays a crucial role in regulating osteoblast differentiation, cell proliferation, and ovarian follicle development. Therefore, how to artificially control BMPR1B and thereby regulate downstream gene expression and physiological processes is a research hotspot in the biomedical field.

[0004] Summary of the Invention

[0005] Based on this, it is necessary to provide an induction culture medium, an induction method and the application of a BMPR1B inhibitor.

[0006] In a first aspect of the present application, an induction culture medium is provided, comprising a BMPR1B inhibitor;

[0007] The BMPR1B inhibitor has a structure represented by Formula I or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope label, isomer or prodrug of the structure represented by Formula I;

[0008] Wherein, ring A is selected from any of the following structures:

[0009] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0010] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl;

[0011] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0012] “*” indicates the attachment site.

[0013] A second aspect of the present application provides a method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps:

[0014] The pluripotent stem cells were adherently cultured using the aforementioned induction medium to obtain neural lineage cells.

[0015] The third aspect of the present application provides the use of the aforementioned BMPR1B inhibitor in inducing the differentiation of pluripotent stem cells into neural lineage cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 shows the specificity of pyrazole-based piperazinone compounds binding to their targets based on kinase activity screening; Figure 1A shows the effect analysis of compound II-1 on the enzymatic activity of 330 kinases; Figures 1B and 1C show the kinase activity test results of compound II-1 at different concentrations against TGFBR1 and BMPR2;

[0017] Figure 2 shows information on the interaction between compounds and BMPR1B in the pyrazole-piperazinone compound-BMPR1B complex displayed by PyMol software; wherein the compound in Figure 2A is II-13, the compound in Figure 2B is II-11, the compound in Figure 2C is II-2, and the compound in Figure 2D is II-1;

[0018] FIG3 shows the details of the Western blot experiment in Example 3; wherein “12 hr” means 12 hours, “24 hr” means 24 hours, and “36 hr” means 36 hours;

[0019] Figure 4 shows the changes in mRNA expression levels of marker genes after treatment of H9 cells with different concentrations of Compound II-1; Figure 4A shows the mRNA expression level of the NANOG gene after 7 days of treatment; Figure 4B shows the mRNA expression level of the PAX6 gene after 7 days of treatment; Figure 4C shows the mRNA expression level of the NANOG gene after 14 days of treatment; Figure 4D shows the mRNA expression level of the PAX6 gene after 14 days of treatment;

[0020] Figure 5 shows the changes in mRNA expression levels of marker genes after treatment of H1 cells with different concentrations of Compound II-13; Figure 5A shows the mRNA expression level of the MAP2 gene after 7 days of treatment; Figure 5B shows the mRNA expression level of the SOX9 gene after 7 days of treatment; Figure 5C shows the mRNA expression level of the MAP2 gene after 14 days of treatment; Figure 5D shows the mRNA expression level of the SOX9 gene after 14 days of treatment;

[0021] Figure 6 shows the changes in mRNA expression levels of marker genes after treatment of induced pluripotent stem cells (iPSCs) with different concentrations of compound II-13; Figure 6A shows the mRNA expression level of the SOX1 gene after 7 days of treatment; Figure 6B shows the mRNA expression level of the SOX5 gene after 7 days of treatment; Figure 6C shows the mRNA expression level of the VIMENTIN (VIM) gene after 7 days of treatment; Figure 6D shows the mRNA expression level of the SOX1 gene after 14 days of treatment; Figure 6E shows the mRNA expression level of the SOX5 gene after 14 days of treatment; Figure 6F shows the mRNA expression level of the VIMENTIN (VIM) gene after 14 days of treatment. DETAILED DESCRIPTION

[0022] To facilitate understanding of the present application, a more comprehensive description of the present application will be provided below with reference to the accompanying drawings. The accompanying drawings illustrate preferred embodiments of the present application. However, the present application may be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a more thorough and comprehensive understanding of the disclosure of the present application.

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0024] In this application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0025] In this application, when referring to numerical ranges, unless otherwise specified, the numerical ranges are considered continuous and include the minimum and maximum values ​​of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe a feature or characteristic, the ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges subsumed therein.

[0026] Unless otherwise specified, the percentage contents mentioned in this application refer to mass percentage for solid-liquid mixture and solid-solid mixture, and refer to volume percentage for liquid-liquid mixture.

[0027] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0028] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows for temperature fluctuations within the precision range of instrument control.

[0029] Explanation of terms

[0030] The term "alkyl" refers to a monovalent residue formed by the loss of a hydrogen atom from a saturated hydrocarbon containing a primary (normal) carbon atom, a secondary carbon atom, a tertiary carbon atom, a quaternary carbon atom, or a combination thereof. Phrases containing this term, for example, "C1-C6 alkyl" refers to an alkyl group containing 1 to 6 carbon atoms, each occurrence of which can be independently C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl or C6 alkyl. Suitable examples include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3 )2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)C H(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2) and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3.

[0031] The term "alkoxy" refers to a group having the structure -O-alkyl, i.e., an alkyl group as defined above attached to the adjacent group via an oxygen atom. Phrases containing this term, for example, "C1-C6 alkoxy" means that the alkyl portion contains 1 to 6 carbon atoms, and each occurrence can be independently C1 alkoxy, C4 alkoxy, C5 alkoxy, or C6 alkoxy. Suitable examples include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-O-CH2CH3 or -OEt), and tert-butoxy (-OC(CH3)3 or -OtBu).

[0032] "Aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing a hydrogen atom. It can be a monocyclic aromatic group, a condensed aromatic group, or a polycyclic aromatic group. For polycyclic aromatic groups, at least one of them is an aromatic ring system. For example, "C6-C 10 "Aryl" refers to an aromatic group containing 6 to 10 carbon atoms, each occurrence of which can be independently C6 aryl, C7 aryl, C8 aryl, C9 aryl or C 10 Suitable examples include, but are not limited to, benzene, biphenyl, naphthalene, and their derivatives.

[0033] "Heteroaryl" means that at least one carbon atom in an aryl or cyclopentadienyl group is replaced by a non-carbon atom, which may be a nitrogen atom, an oxygen atom, or a sulfur atom. For example, "C3-C 10 The term "heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, which, at each occurrence, is independently C3 heteroaryl, C4 heteroaryl, C5 heteroaryl, C6 heteroaryl, C7 heteroaryl or C8 heteroaryl. Suitable examples include, but are not limited to, furan, benzofuran, thiophene, benzothiophene, pyrrole, pyrazole, triazole, imidazole, oxazole, oxadiazole, thiazole, tetrazole, indole, carbazole, pyrroloimidazole, pyrrolopyrrole, thienopyrrole, thienothiophene, furopyrrole, furofuran, thienofuran, benzisoxazole, benzisothiazole, benzimidazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, quinoline, isoquinoline, o-naphthyridine, quinoxaline, phenanthridine, primidine, quinazoline and quinazolinone.

[0034] As used herein, "prodrug" refers to any compound that, when administered to an organism, produces a drug, i.e., an active ingredient, as a result of a spontaneous chemical reaction, an enzyme-catalyzed chemical reaction, photolysis, and / or metabolic chemical reaction. Prodrugs are therefore covalently modified analogs or latent forms of therapeutically active compounds. Suitable examples include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo compound, phosphoramide, glucoside, ether, acetal, and the like forms of the compound.

[0035] "Pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0036] A "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, and maltose. Rice oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other nontoxic compatible substances used in pharmaceutical formulations.

[0037] "Pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound of the structure shown with an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present application with an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by a compound of the present invention and a base. Suitable bases for forming salts include, but are not limited to, alkali metal salts (e.g., sodium salts or potassium salts), alkaline earth metal salts (e.g., magnesium salts or calcium salts), ammonium salts (e.g., lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example, methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0038] "Pharmaceutically acceptable esters and amides" refer to esters or amides formed by any compound in the structure shown and other compounds that are suitable for use as drugs. Pharmaceutically acceptable esters include organic esters and inorganic esters.

[0039] When the compound represented by Formula I has a carboxyl group, the compound represented by Formula I or its active derivative (e.g., acid chloride, mixed acid anhydride, etc.) can be reacted with the corresponding alcohol (e.g., C1-C6 alcohol, etc.) or its active derivative (e.g., (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl body, (pivaloyloxy)methyl body, benzofuranone body, (isopropoxycarbonyl)oxymethyl body, etc.), or ammonia or the corresponding amine (mono-C1-C6 alkylamine- or di-C1-C6 alkylamine, etc.) according to conventional methods (condensation reaction of carboxylic acids with alcohols or amines); the ester of the compound represented by Formula I can be reacted with the corresponding alcohol (e.g., C1-C6 alcohol, etc.) (ester exchange reaction), or ammonia or the corresponding amine (mono-C1-C6 alkylamine or di-C1-C6 alkylamine, etc.) (amidation reaction). or reacting an alkali metal salt of the compound represented by Formula I with a corresponding halide (e.g., C1-C6 alkyl chloride or bromide, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl chloride or bromide, (pivaloyloxy) methyl chloride or bromide, benzofuranone chloride or bromide, [(isopropoxycarbonyl)oxy] methyl chloride or bromide, etc.) to produce pharmaceutically acceptable esters or amides. Similarly, when the compound represented by Formula I has a hydroxyl group, the compound represented by Formula I can be subjected to a condensation reaction with a carboxylic acid, an acyl chloride, an acid anhydride, etc. according to conventional methods to obtain pharmaceutically acceptable esters.

[0040] The aforementioned esters may be, for example, C1-C6 alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, sec-butyl ester, tert-butyl ester, pentyl ester, and hexyl ester; C3-C6 cycloalkyl esters such as cyclopentyl ester and cyclohexyl ester; C6-C6 cycloalkyl esters such as phenyl ester and naphthyl ester; 10 Aryl esters; benzyl ester, phenylethyl ester, α-methylbenzyl ester, 3-phenylpropyl ester, 4-phenylbutyl ester, 6-phenylhexyl ester, diphenylmethyl ester, triphenylmethyl ester, etc. C6-C 10 Aryl C1-C6 alkyl esters; or esters that can be hydrolyzed in vivo, such as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (pivaloyloxy)methyl ester, benzofuranonyl ester, [(isopropoxycarbonyl)oxy]methyl ester, [(cyclohexyloxycarbonyl)oxy]methyl ester, and 1-[(cyclohexyloxycarbonyl)oxy]ethyl ester.

[0041] The aforementioned amides may be, for example, amide (-CONH2); mono-C1-C6 alkylamides or mono-C3-C6 cycloalkylamides such as N-formamide, N-acetamide, N-propionamide, N-isopropylamide, N-butyramide, N-sec-butyramide, N-tert-butyramide, N-pentanamide, N-hexanamide, N-cyclopropanamide, N-cyclopentanamide, and N-cyclohexanamide; or N,N-diformamide, N,N-diethylamide, N,N-dipropylamide, N-isopropylamide, N-butyramide, N-sec-butyramide, N-tert-butyramide, N-pentanamide, N-hexanamide, N-cyclopropanamide, N-cyclopentanamide, and N-cyclohexanamide; N-C1-C6 alkylamides, N-C1-C6 alkyl-N-C3-C6 cycloalkylamides or di-C3-C6 cycloalkylamides such as amide, N,N-diisopropylamide, N-methyl-N-acetamide, N-methyl-N-propionamide, N-methyl-N-butyramide, N-ethyl-N-propionamide, N-ethyl-N-butyramide, N-butyl-N-cyclopentylamide, N-ethyl-N-cyclopropionamide, N,N-dicyclohexylamide, etc.

[0042] "Solvate" refers to a complex formed by the compound represented by general formula (I) and solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the compound of the present application and water.

[0043] "Active metabolite" refers to an active derivative of a compound that is formed when the compound is metabolized.

[0044] "Polymorphs" refer to compounds of the present invention that exist in different crystal lattice forms.

[0045] "Isotope-labeled" refers to a compound of the present invention that is isotopically labeled. For example, the isotopes in the compound of the present invention may include various isotopes of elements such as H, C, N, O, P, F, and S, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 S.

[0046] "Isomers" refer to isomers produced by the different spatial arrangement of atoms in a molecule. The compounds of the present application contain structures such as asymmetric or chiral centers, double bonds, etc. Therefore, the compounds of the present application may include multiple isomeric forms such as optical isomers, geometric isomers, tautomers, atropisomers, and these isomers and their single isomers, racemates, etc. are all included in the scope of the present application. For example, for optical isomers, optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral resolution, chiral synthesis or chiral reagents or other conventional techniques. For example, diastereomers can be converted into by reacting with appropriate optically active substances (such as chiral alcohols or Mosher's acyl chlorides), which are separated and converted (such as hydrolyzed) into corresponding single isomers. For another example, separation can also be carried out by chromatographic column.

[0047] Neurodegenerative diseases and neural damage have a fatal impact on human health and are often difficult to cure. With the development of stem cell biology, neuroscience and reprogramming technology, some effective treatments have been developed. For example, stem cell replacement therapy can be used for central and peripheral nervous system diseases and injuries, using neurons and other neural cells to regenerate affected neural tissue. One of the main strategies to achieve the above ultimate goal is to reshape the normal development of the nervous system by activating the endogenous regenerative ability of neural stem cells or transplanting neural or embryonic cells. Although the use of stem cells in neurological diseases is very popular, there are also some severe challenges. For example, how to control the efficient and stable directional differentiation of stem cells has always been a problem that the field of stem cell biology research aims to solve.

[0048] Based on the above background, the first aspect of the present application provides an induction culture medium comprising a BMPR1B inhibitor;

[0049] The BMPR1B inhibitor has a structure represented by Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled form, isomer, or prodrug of the structure represented by Formula I;

[0050] Wherein, ring A is selected from any of the following structures:

[0051] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0052] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl;

[0053] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0054] “*” indicates the attachment site.

[0055] The culture medium provided in the present application contains a BMPR1B inhibitor, which is a pyrazole-1-piperazinone compound with a specially designed structure. It can form a relatively stable complex with BMPR1B through hydrogen bond interactions and hydrophobic interactions, thereby controlling BMPR1B and further regulating downstream gene expression and physiological processes, so that pluripotent stem cells can efficiently and directionally differentiate into neural lineage cells, providing a possible approach for the use of stem cell biology in the treatment of neurodegenerative diseases and nerve damage.

[0056] In some embodiments, Y is -(CH2) n -, n is 0, 1 or 2; preferably, Y is -(CH2) n -, n is 0 or 1; further preferably, Y is -(CH2) n -, n is 0 or 1.

[0057] In some embodiments, R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1~C6 alkyl, C6~C 10 Aryl or C3~C 10 Heteroaryl; preferably, R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C3-C6 heteroaryl; further preferably, R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; more preferably, R 1 Selected from -H, -D, or any of the following substituents:

[0058] Wherein, “*” indicates the connection site.

[0059] When R 1 When selected from heteroaryl groups, especially heteroaryl groups substituted with methyl or hydroxyl groups, the formed pyrazolylpiperazinone compounds have higher binding energy with the docking target of BMPR1B and lower physiological toxicity, which is beneficial to improving the efficacy and biocompatibility of pyrazolylpiperazinone compounds as BMPR1B inhibitors.

[0060] In some embodiments, R2 Selected from -OH or C1-C6 alkyl; preferably, R 2 is selected from -OH or C1-C4 alkyl; further preferably, R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

[0061] In some embodiments, the BMPR1B inhibitor has a structure as shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer, or prodrug of the structure as shown in any one of Formulas I-1 to I-13;

[0062] In some embodiments, the BMPR1B inhibitor has a structure shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled form, isomer, or prodrug of the structure shown in Formula II;

[0063] Among them, A ring, Y and R 1 As defined in any of the preceding embodiments.

[0064] In some embodiments, the BMPR1B inhibitor has a structure as shown in any one of Formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer, or prodrug of the structure as shown in any one of Formulas II-1 to II-13;

[0065] In some embodiments, the concentration of the BMPR1B inhibitor is 1 μM to 50 μM, preferably, the concentration of the BMPR1B inhibitor is 1 μM to 20 μM, and further preferably, the concentration of the BMPR1B inhibitor is 1 μM to 10 μM. Alternatively, the concentration of the BMPR1B inhibitor can be, for example, 2.5 μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM, or 45 μM. An appropriate concentration of the BMPR1B inhibitor can more efficiently promote the directed differentiation of pluripotent stem cells into neural lineage cells without causing damage.

[0066] In some embodiments, the induction medium further comprises one or more of a basal medium, growth factors, inorganic salts, and additives;

[0067] The growth factors include one or more of vitamins, progesterone, 1,4-butanediamine and insulin;

[0068] The additives include one or more of piperidinol oxide, luteolin, D(+)-galactose and recombinant human transferrin.

[0069] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0070] (1) The basal medium is DMEM or DMEM-F12, and the basal medium is supplemented with minimum essential amino acids;

[0071] (2) Vitamins include one or more of vitamin E, vitamin B12, and vitamin C;

[0072] (3) Inorganic salts include one or more of sodium chloride and sodium selenite.

[0073] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0074] (1) Growth factors include vitamins, 2.0 ng / mL to 15 ng / mL progesterone, 2 μg / mL to 50 μg / mL 1,4-diamine, and 5 mg / L to 40 mg / L insulin, and vitamins include 0.1 μg / mL to 15 μg / mL vitamin E, 0.5 μM to 2.4 μM vitamin B12, and 32 mg / L to 128 mg / L vitamin C;

[0075] (2) Inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite;

[0076] (3) Additives include 10 μM to 200 μM piperidinol oxide, 5 μM to 150 μM luteolin, 5 μg / mL to 25 μg / mL D(+)-galactose, and 50 ng / mL to 200 ng / mL recombinant human transferrin.

[0077] In some embodiments, the induction medium satisfies one or more of the following conditions:

[0078] (1) Growth factors include vitamins, 6.3 ng / mL progesterone, 23 μg / mL 1,4-diamine, and 22 mg / L insulin, and vitamins include 1 μg / mL vitamin E, 1.2 μM vitamin B12, and 64 mg / L vitamin C;

[0079] (2) Inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite;

[0080] (3) Additives included 50 μM piperidinol oxide, 60 μM luteolin, 12.5 μg / mL D(+)-galactose, and 100 ng / mL recombinant human transferrin.

[0081] A second aspect of the present application provides a method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps:

[0082] Adherent culture of pluripotent stem cells is performed using the induction medium described in any of the aforementioned embodiments to obtain neural lineage cells.

[0083] In some embodiments, NANOG is used as a marker for identifying pluripotent stem cells, and PAX6 is used as a marker for identifying neural lineage cells. Because NANOG is expressed only in pluripotent stem cells, and PAX6 is expressed only in neural lineage cells, selecting these two as identification markers allows for quantitative tracking of pluripotent stem cell differentiation into neural lineage cells and verification of induction results.

[0084] In some embodiments, the adherent culture is performed in the presence of a basement membrane preparation. Preferably, the basement membrane preparation comprises one or more of matrigel, laminin, and vitronectin.

[0085] In some embodiments, the pluripotent stem cells are mammalian pluripotent stem cells. Alternatively, the pluripotent stem cells are human pluripotent stem cells, which can be, for example, H9 cell lines or H1 cell lines, or human induced pluripotent stem cells (e.g., obtained by reprogramming from CD34+ cells using the method of CN109628383B).

[0086] In some embodiments, the neural lineage cells include one or more of neural progenitor cells, neurons, astrocytes, and oligodendrocytes.

[0087] The third aspect of the present application provides use of the BMPR1B inhibitor mentioned in the induction medium described in any of the aforementioned embodiments in inducing pluripotent stem cells to differentiate into neural lineage cells.

[0088] Compound synthesis (In the following content, if there is a discrepancy between the compound name and the structural formula, the structural formula shall prevail):

[0089] Synthesis Route A

[0090] Intermediate M1-n (0.12 mmol), (4aS,8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 380 mg, 1 mmol) were mixed. N,N-diisopropylethylamine (DIEA, 2 mL) and N,N-dimethylformamide (DMF, 20 mL) were then added and stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 3:7) to obtain the desired product II-n.

[0091] Compounds II-1 and II-13 were obtained via synthetic route A:

[0092] II-1:

[0093] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0094] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (12 mg, 41%), LC-MS m / z=289.2 [M+H] + .

[0095] II-13:

[0096] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0097] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (17 mg, 57%), LC-MS m / z=299.2 [M+H] + .

[0098] Synthesis Route B

[0099] Compound II-12 was obtained via synthetic route B:

[0100] II-12:

[0101] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0102] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0103] (1) To a solution of 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-1, 0.167 g, 1 mmol) in 2 mL of 1 mol / L NaOH and 0.6 mL of 1,4-dioxane was added dropwise 0.25 g (1.1 mmol) of di-tert-butyl dicarbonate (Boc2O) in 1.5 mL of 1,4-dioxane at 0°C. The reaction mixture was stirred at 0°C for 0.5 h and then reacted at room temperature overnight, maintaining the pH at 8-9. After the reaction, the mixture was diluted with 5 mL of H2O and extracted with n-hexane. The aqueous phase was acidified to pH 2-3 with citric acid and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-2, 200 mg, 75%), LC-MS m / z = 268.1 [M+H] + ;

[0104] (2) M3-2 (20 mg, 0.075 mmol) was mixed with (4aS,8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 38 mg, 0.1 mmol). N,N-diisopropylethylamine (DIEA, 0.2 mL) and N,N-dimethylformamide (DMF, 2 mL) were added, and the mixture was stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane=3:7) to give tert-butyl 3-((4aS,8aS)-3-oxodeoxyquinoline-1-carbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (M3-3, 18 mg, 60%), LC-MS m / z=404.2 [M+H] + ;

[0105] (3) M3-3 (18 mg, 0.04 mmol) and trifluoroacetic acid (TFA, 35 mg, 0.3 mmol) were added to 2 mL of dichloromethane (DCM) and stirred at room temperature for half an hour. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The obtained product was II-12 (13 mg, 96%), LC-MS m / z = 304.2 [M+H] + .

[0106] Synthetic Route C

[0107] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of M1-n (21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise thereto over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain M5-n;

[0108] (2) In a 20 mL reactor, R 1 -YX (0.698 mmol, wherein X represents halogen, R 1 and Y are as defined above), (4aS,8aS)-octahydroquinoxalin-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.) and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and sparged with nitrogen for 10 minutes. The reaction mixture was heated to 70°C and maintained for 90 minutes. The mixture was filtered, washed with dichloromethane, and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give M6-n;

[0109] (3) M6-n (1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and M5-n (1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea hexafluorophosphate (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture and stirred overnight. The reaction was monitored by thin layer chromatography. When the reactants were no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether: ethyl acetate) to obtain M7-n;

[0110] (4) To a solution of M7-n (3.95 mmol) in tetrahydrofuran (39.5 mL) was added triethylsilane (2.30 g, 19.8 mmol) at 5°C and stirred at room temperature for 3 hours. The reaction mixture was concentrated, rinsed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to obtain the desired product II-n.

[0111] Compounds II-2 to II-10 were obtained via synthetic route C:

[0112] II-2:

[0113] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0114] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1504 mg, 99%). LC-MS m / z = 384.2 [M+H] + .

[0115] II-3:

[0116] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0117] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1445 mg, 99%). LC-MS m / z = 370.2 [M+H] + .

[0118] II-4:

[0119] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0120] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1507 mg, 99%). LC-MS m / z = 386.2 [M+H] + .

[0121] II-5:

[0122] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0123] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1469 mg, 98%). LC-MS m / z = 380.2 [M+H] + .

[0124] II-6:

[0125] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0126] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1484 mg, 99%). LC-MS m / z = 380.2 [M+H] + .

[0127] II-7:

[0128] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0129] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z = 382.2 [M+H] + .

[0130] II-8:

[0131] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0132] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z = 382.2 [M+H] + .

[0133] II-9:

[0134] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0135] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1488 mg, 99%). LC-MS m / z = 381.2 [M+H] + .

[0136] II-10:

[0137] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0138] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1413 mg, 94%). LC-MS m / z = 381.2 [M+H] + .

[0139] Synthetic Route D

[0140] Compound II-11 was obtained via synthetic route D:

[0141] II-11:

[0142] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0143] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0144] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of 5-methyl-1H-pyrazole-4-carbaldehyde (M8-1, 2.37 g, 21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to give 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carbaldehyde (M8-2, 4.96 g, 96%). LC-MS m / z=240.1[M+H] + ;

[0145] (2) In a 20 mL reactor, M8-2 (168 mg, 0.698 mmol), (4aS,8aS)-octahydroquinoxalin-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.), and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and sparged with nitrogen for 10 minutes. The reaction mixture was heated to 70°C and maintained for 90 minutes. The mixture was filtered, washed with dichloromethane, and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give (4aS,8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)octahydroquinoxalin-2(1H)-one (M8-3, 244 mg, 92.2%). LC-MS m / z = 378.3 [M+H] + ;

[0146] (3) M8-3 (379 mg, 1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL). 1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid (M8-4, 339 mg, 1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea hexafluorophosphate azobenzotriazole (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture, and the mixture was stirred overnight. The reaction was monitored by thin layer chromatography. When the reactant was no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether:ethyl acetate) to give (4aS,8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopentanopyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (M8-5, 424 mg, 66%). LC-MS m / z = 642.4 [M+H] + ;

[0147] (4) Triethylsilane (2.30 g, 19.8 mmol) was added to a solution of M8-5 (2540 mg, 3.95 mmol) in tetrahydrofuran (39.5 mL) at 5°C and stirred at room temperature for 3 hours. The reaction mixture was concentrated, rinsed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to give II-11 (1510 mg, 99%). LC-MS m / z = 383.2 [M+H] + .

[0148] Example 1

[0149] AutoDock Vina software was used to perform molecular docking of the pyrazolylpiperazinone compounds described in this application with the BMPR1B target protein, generating 13 docking conformations. The binding energy and ligand efficiency of each optimal docking result for the pyrazolylpiperazinone compound with the BMPR1B target protein were calculated. The docking results were then integrated to screen pyrrolopyridine molecules. The specific docking results are shown in Table 1. The second column of Table 1 shows the binding free energy calculated by AutoDock Vina molecular docking software. The more negative the value, the stronger the binding ability of the compound to the target protein. The predicted values ​​show that the absolute values ​​of the binding energy of the pyrazolylpiperazinone compounds are all far greater than the threshold of 3 set based on the target characteristics.

[0150] The cytotoxicity of the pyrazolylpiperazinone compounds in this application was predicted using eToxPred software. The toxicity calculation results of each pyrazolylpiperazinone compound are shown in column 3 of Table 1. The predicted values ​​show that the toxicity of the pyrazolylpiperazinone compounds is less than the threshold value of 0.58 (greater than 0.58 indicates possible toxicity).

[0151] Table 1. Molecular docking binding energy and molecular toxicity prediction of pyrazole-1-piperazinones

[0152] Example 2

[0153] 330 kinase candidates (15-50 nM, 2.5 μL) were mixed with compound II-1 (2.5 mM, 25 nL, prepared in DMSO) and incubated at 25°C for 10 minutes. Then, a mixture of kinase peptide substrate (0.2 mg / mL; supplier: GenScript) and ATP (10-60 μM; supplier: Promega; product number: V915B) (2.5 μL in total, prepared in assay buffer) was added to the mixture, and the mixture was reacted at 25°C for 60-120 minutes. Finally, HTRF was used. 1 or ADP-Glo 2 The reaction products were quantitatively detected. During the kinase activity assay, the consumption of each substrate was less than 10%, and two technical replicates were performed for each kinase activity assay.

[0154] The results showed that II-1 had a significant inhibitory effect on the kinase activity of BMPR1B (Figure 1A; Note: All test results are shown. For ease of reading, the x-axis only shows the name of one kinase for every 10 kinases). However, at the same concentration, II-1 had no inhibitory effect on the kinase activity of TGFBR1 and BMPR2, and at different concentrations (the highest concentration was 12.5 μM, and the concentration was 3-fold serially diluted), there was no inhibitory effect on TGFBR1 and BMPR2 kinases (Figure 1B, C). This result confirms the specific binding ability of II-1 to the target site.

[0155] In order to investigate the above experimental results at the structural level, PyMol software (supplier: ) Structural analysis of the complexes formed by compounds II-1, II-2, II-11, and II-13 with BMPR1B was performed. As shown in Figure 2, the complex structure was obtained by molecular docking. The N- and C-terminal domains of BMPR1B are shown as cartoon models of different shapes, the loop structure of BMPR1 and the loop structure that stimulates catalytic activity (activation loop) are shown as cartoon models of different grayscales, the pyrazolylpiperazinone compounds are shown as stick ring models, the interacting amino acid main chain / side chain are shown as stick models, hydrogen bond interactions are shown as solid lines, and hydrophobic interactions are shown as dotted lines. This result also shows that pyrazolylpiperazinone compounds have structural characteristics that bind to BMPR1B.

[0156] Example 3

[0157] Western blot analysis further validated the inhibitory effect of pyrazolylpiperazinone compounds on the BMP signaling pathway. First, 1.5 × 10^6 cells of the commercial human pluripotent stem cell line H1 were seeded into 6-well cell culture plates with 2 mL of culture medium per well. After one day of culture, the medium was replaced and 6 μL of 30 μM pyrazolylpiperazinone compound II-I was added. After treatment for 12, 24, and 36 hours, the cells were digested and protein samples were prepared. Sample preparation followed the instructions of the commercial kit (Beyotime Biotechnology; Cat. No. P0013). Western blot analysis was performed as described in the literature (H. Zhang et al., 2022; N. Zhang et al., 2021). The results showed that within 24 hours of treatment, pyrazolylpiperazinone compound II-I did not inhibit the phosphorylation of SMAD2 / 3, downstream signaling proteins of the TGF signaling pathway, but showed a significant inhibitory effect on the phosphorylation of SMAD1 / 5 / 8, downstream signaling proteins of the BMP signaling pathway (Figure 3). These results further indicated that pyrazolylpiperazinone compound II-I selectively inhibited the BMP signaling pathway, which was consistent with the results of kinase activity assay ( Figure 1B, C ).

[0158] Table 2 Antibody information

[0159] Example 4: Induction and identification of neural lineages

[0160] (1) Culture medium formulation

[0161] Dulbecco's Modified Eagle's Medium (DMEM), Minimum Essential Medium Non-Essential Amino Acids (Cat. No.: 11140076, Thermo Fisher), piperidinol oxide (4-Hydroxy-TEMPO, concentration of 50 μM), D(+)-galactose (D(+)-galactose, concentration of 12.5 μg / mL), vitamin E (concentration of 1 μg / mL), vitamin B12 (concentration of 1.2 μM), vitamin C (concentration of 64 mg / L), progesterone (concentration of 6.3 ng / mL), 1,4-butanediamine (concentration of 23 μg / mL), luteolin (concentration of 60 μM), sodium chloride (concentration of 0.5 g / L), sodium arsenate (concentration of 13.6 μg / L), insulin (concentration of 22 μg / mL), recombinant human transferrin (concentration of 100 ng / mL) and the BMPR1B inhibitor of the present invention (induction medium A uses BMPR1B inhibitor II-1, and induction medium B uses BMPR1B inhibitor II-13).

[0162] (2) Expansion and passage of pluripotent stem cells

[0163] Commercial human pluripotent stem cell lines H1 and H9 and induced pluripotent stem cell (iPSC) lines were used for the study. Induced pluripotent stem cells were prepared using CD34+ cells reprogrammed according to the "Reprogramming medium, i.e., culture method for reprogramming induced pluripotent stem cells" (CN109628383A, Example 2). Matrigel (STEMCELL Technologies) was used to coat T25 cell culture flasks, which were plated and incubated in a 37°C incubator for more than one hour. The cells were cultured at a rate of 1×10 6 The cells were seeded in T25 culture flasks for expansion and passage.

[0164] (3) Neural induction

[0165] 6-well culture plates were coated with 50 μg / mL poly-lysine (SIGMA, Catalog No.: P6407) and incubated in a 37°C incubator for more than 3 hours. 5 μg / mL laminin (SIGMA ALDRICH, Catalog No.: I2020) was then used for further coating and incubated in a 37°C incubator for more than 3 hours. When the pluripotent stem cells reached 70% coverage, they were digested with EDTA at 37°C for 5 minutes and then terminated with DMEM. After washing and centrifugation, the cells were plated at 2×10 5The cells from each flask were reseeded in T25 culture plates. Induction was performed using the aforementioned induction medium. Specifically, pluripotent stem cells H9 were induced using induction medium A, and pluripotent stem cells H1 and induced pluripotent stem cells were induced using induction medium B, respectively. The medium was changed daily until day 14.

[0166] (4) Sequence detection and data analysis and processing

[0167] Samples were collected on days 7 and 14 of induction and processed using the VAHTS Universal V8 RNA-seq Library Prep Kit for Illumina (Vazyme, NR605-01 / 02). Sequencing was performed using Illumina. After obtaining raw sequencing data, FASTP, HISAT2, and FeatureCounts were used to analyze the data and determine gene expression levels. GAPDH was used as a reference gene to calibrate mRNA expression levels across transcriptomes.

[0168] The analysis found that as the concentration of the BMPR1B inhibitor II-1 increased, the expression of the marker gene NANOG of the pluripotent stem cell H9 treated with the BMPR1B inhibitor decreased (P<0.05, t-test). At the same time, the expression of the marker gene PAX6 of the neural progenitor cell increased (P<0.05, t-test), indicating that the system showed a dose-dependent effect on II-1 during the induction process; from day 7 to day 14, as the induction time increased, the expression of NANOG decreased and the expression of PAX6 increased (Figure 3, error bars represent the standard deviation of 3 biological replicates). These results indicate that the BMPR1B inhibitor II-1 provided in this application has the effect of promoting the differentiation of pluripotent stem cells into neural progenitor cells (Figure 4B, D).

[0169] In addition, as the concentration of the BMPR1B inhibitor II-13 increased, the expression of the neuronal marker gene MAP2 (A. Caceres, Developmental Brain Research. Volume 13, Issue 2, April 1984, Pages 314-318) and the glial progenitor cell marker gene Sox9 (Neyrinck, K et al., Stem Cell Rev and Rep 17, 185521)) in the pluripotent stem cells H1 treated with the BMPR1B inhibitor showed a dose-dependent effect on II-13 (Figure 5).

[0170] Furthermore, compared with the induced pluripotent stem cells of the control group that were not treated with the BMPR1B inhibitor, the expression of key genes such as neuronal precursor marker genes Sox1, Sox5 (Elkouris M et al., Stem Cells. 2011; 29(1): 89–98; Tina Lai et al., Neuron V57(2): 232-247, 2008) and nervous system differentiation marker gene VIM (Sofia Duarte et al., Nature Communications volume 10, 4200(2019)) in the induced pluripotent stem cells after treatment with the BMPR1B inhibitor II-13 was significantly increased, and also showed a dose-dependent effect on II-13 (Figure 6). These results show that the BMPR1B inhibitor provided by the present application can not only promote the differentiation of pluripotent stem cells into neural progenitor cells, but also has the effect of promoting the formation and differentiation of various neural cells.

[0171] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0172] The above-described embodiments merely represent several implementation methods of the present application, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the invention. A person skilled in the art would be able to make various modifications and improvements without departing from the concept of the present application, and these modifications and improvements fall within the scope of protection of the present application. Therefore, the scope of protection of the patent application shall be based on the appended claims, and the description and drawings may be used to interpret the content of the claims.

Claims

1. An induction medium comprising a BMPR1B inhibitor; The BMPR1B inhibitor has a structure as shown in Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure as shown in Formula I; in, Ring A is selected from any of the following structures: Y is -(CH2) n -, n is 0, 1, 2 or 3; R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl; R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy; "*" indicates the attachment site.

2. The induction medium according to claim 1, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0, 1 or 2; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C6-C 10 Aryl or C3~C 10 heteroaryl; (3)R 2 Selected from -OH or C1~C6 alkyl.

3. The induction medium according to claim 2, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C3-C6 heteroaryl; (3)R 2 Selected from -OH or C1~C4 alkyl.

4. The induction medium according to claim 3, characterized in that The BMPR1B inhibitor meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; (3)R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

5. The induction medium according to any one of claims 1 to 4, characterized in that R 1 Selected from -H, -D or any of the following substituents: Wherein, "*" indicates the connection site.

6. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in any one of Formulas I-1 to I-13; 7. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure shown in Formula II; Among them, ring A, Y and R 1 As defined in any one of claims 1 to 4.

8. The induction medium according to any one of claims 1 to 4, characterized in that The BMPR1B inhibitor has a structure shown in any one of Formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled, isomer or prodrug of the structure shown in any one of Formulas II-1 to II-13; 9. The induction medium according to any one of claims 1 to 4, characterized in that The concentration of the BMPR1B inhibitor is 1 μM to 50 μM.

10. The induction medium according to any one of claims 1 to 4, characterized in that The induction medium further comprises one or more of a basal medium, growth factors, inorganic salts and additives; Wherein, the growth factors include one or more of vitamins, progesterone, 1,4-butanediamine and insulin; The additives include one or more of piperidinol oxide, luteolin, D(+)-galactose and recombinant human transferrin.

11. The induction medium according to claim 10, characterized in that The induction medium meets one or more of the following conditions: (1) The basal medium is DMEM medium or DMEM-F12 medium, and the basal medium is supplemented with minimum essential medium non-essential amino acids; (2) The vitamins include one or more of vitamin E, vitamin B12 and vitamin C; (3) The inorganic salt includes one or more of sodium chloride and sodium selenite.

12. The induction medium according to claim 11, characterized in that The induction medium meets one or more of the following conditions: (1) The growth factors include vitamins, 2.0 ng / mL to 15 ng / mL of progesterone, 2 μg / mL to 50 μg / mL of 1,4-butanediamine, and 5 mg / L to 40 mg / L of insulin, and the vitamins include 0.1 μg / mL to 15 μg / mL of vitamin E, 0.5 μM to 2.4 μM of vitamin B12, and 32 mg / L to 128 mg / L of vitamin C; (2) The inorganic salts include 0.5 g / L sodium chloride and 13.6 μg / L sodium selenite; (3) The additives include 10 μM to 200 μM piperidinol oxide, 5 μM to 150 μM luteolin, 5 μg / mL to 25 μg / mL D(+)-galactose, and 50 ng / mL to 200 ng / mL recombinant human transferrin.

13. A method for inducing pluripotent stem cells to differentiate into neural lineage cells, comprising the following steps: Adhesion culture of pluripotent stem cells using the induction medium described in any one of claims 1 to 12 to obtain neural lineage cells.

14. Use of the BMPR1B inhibitor in the induction medium according to any one of claims 1 to 12 in inducing differentiation of pluripotent stem cells into neural lineage cells.

Citation Information

Patent Citations

  • Reprogrammed culture medium and culture method of reprogrammed induced multipotential stem cell

    CN109628383A

  • Reprogramming culture medium and culture method for reprogrammed induced pluripotent stem cells

    CN109628383B

  • Specification of functional cranial placode derivatives from human pluripotent stem cells

    CN105940101A

  • Efficient and rapid method realizing differentiation of induced pluripotent stem cells towards neural stem cells

    CN108384755A

  • Inhibition of BMP signaling, compounds, compositions and uses thereof

    CN109952293A